Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1371/journal.pone.0162588 http://scihub22266oqcxt.onion/10.1371/journal.pone.0162588 C5025231!5025231!27632175     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       PLoS+One 2016 ; 11 (9): ä Nephropedia Template TP {{tp|p=27632175|t=2016. Statins and Renin Angiotensin System Inhibitors Dose-Dependently Protect Hypertensive Patients against Dialysis Risk |pdf=|usr=}}{{27632175}} gab.com Text Statins and Renin Angiotensin System Inhibitors Dose-Dependently Protect Hypertensive Patients against Dialysis Risk JO: PLoS One http://www.kidney.de/pget.php?&tw=1&pmid=27632175 #FOAvip Background: Taiwan has the highest renal disease incidence and prevalence in the world. We evaluated the association of statin and renin?angiotensin system inhibitor (RASI) use with dialysis risk in hypertensive patients. Methods: Of 248,797 patients who received a hypertension diagnosis in Taiwan during 2001?2012, our cohort contained 110,829 hypertensive patients: 44,764 who used RASIs alone; 7,606 who used statins alone; 27,836 who used both RASIs and statins; and 33,716 who used neither RASIs or statins. We adjusted for the following factors to reduce selection bias by using propensity scores (PSs): age; sex; comorbidities; urbanization level; monthly income; and use of nonstatin lipid-lowering drugs, metformin, aspirin, antihypertensives, diuretics, and beta and calcium channel blockers. The statin and RASI use index dates were considered the hypertension confirmation dates. To examine the dose?response relationship, we categorized only statin or RASI use into four groups in each cohort: <28 (nonusers), 28?90, 91?365, and >365 cumulative defined daily doses (cDDDs). Results: In the main model, PS-adjusted hazard ratios (aHRs; 95% confidence intervals [CIs]) for dialysis risk were 0.57 (0.50?0.65), 0.72 (0.53?0.98), and 0.47 (0.41?0.54) in the only RASI, only statin, and RASI + statin users, respectively. RASIs dose-dependently reduced dialysis risk in most subgroups and in the main model. RASI use significantly reduced dialysis risk in most subgroups, regardless of comorbidities or other drug use (P < 0.001). Statins at >365 cDDDs protected hypertensive patients against dialysis risk in the main model (aHR = 0.62, 95% CI: 0.54?0.71), regardless of whether a high cDDD of RASIs, metformin, or aspirin was used. Conclusion: Statins and RASIs independently have a significant dose-dependent protective effect against dialysis risk in hypertensive patients. The combination of statins and RASIs can additively protect hypertensive patients against dialysis risk. Twit Text FOAVip Statins and Renin Angiotensin System Inhibitors Dose-Dependently Protect Hypertensive Patients against Dialysis Risk ????PLoS One http://www.kidney.de/pget.php?&tw=1&pmid=27632175 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27632175 #FOAvip English Wikipedia <ref>{{Cite pmid|27632175}}</ref> Statins and Renin Angiotensin System Inhibitors Dose-Dependently Protect Hypertensive Patients against Dialysis Risk #MMPMID27632175 Liu JC; Hsu YP; Wu SY PLoS One 2016[]; 11 (9): ä PMID27632175show ga Background: Taiwan has the highest renal disease incidence and prevalence in the world. We evaluated the association of statin and renin?angiotensin system inhibitor (RASI) use with dialysis risk in hypertensive patients. Methods: Of 248,797 patients who received a hypertension diagnosis in Taiwan during 2001?2012, our cohort contained 110,829 hypertensive patients: 44,764 who used RASIs alone; 7,606 who used statins alone; 27,836 who used both RASIs and statins; and 33,716 who used neither RASIs or statins. We adjusted for the following factors to reduce selection bias by using propensity scores (PSs): age; sex; comorbidities; urbanization level; monthly income; and use of nonstatin lipid-lowering drugs, metformin, aspirin, antihypertensives, diuretics, and beta and calcium channel blockers. The statin and RASI use index dates were considered the hypertension confirmation dates. To examine the dose?response relationship, we categorized only statin or RASI use into four groups in each cohort: <28 (nonusers), 28?90, 91?365, and >365 cumulative defined daily doses (cDDDs). Results: In the main model, PS-adjusted hazard ratios (aHRs; 95% confidence intervals [CIs]) for dialysis risk were 0.57 (0.50?0.65), 0.72 (0.53?0.98), and 0.47 (0.41?0.54) in the only RASI, only statin, and RASI + statin users, respectively. RASIs dose-dependently reduced dialysis risk in most subgroups and in the main model. RASI use significantly reduced dialysis risk in most subgroups, regardless of comorbidities or other drug use (P < 0.001). Statins at >365 cDDDs protected hypertensive patients against dialysis risk in the main model (aHR = 0.62, 95% CI: 0.54?0.71), regardless of whether a high cDDD of RASIs, metformin, or aspirin was used. Conclusion: Statins and RASIs independently have a significant dose-dependent protective effect against dialysis risk in hypertensive patients. The combination of statins and RASIs can additively protect hypertensive patients against dialysis risk. äStatins and Renin Angiotensin System Inhibitors Dose-Dependently Prote(epmc).pdf DeepDyve Pubget Overpricing